BRICS Nations Standardized Clinical Regulatory Framework
The new GxP framework aims to align quality standards for biopharma operations across all member nations.
Updated on Oct. 10, 2026 in Economic Policy
Live Poll
Do you believe international collaboration on clinical research standards will result in better medical innovation?
BRICS member nations have developed a shared white paper on Good Clinical, Laboratory, and Manufacturing Practices (GxP). The initiative, codified in the New Delhi Declaration, extends a memorandum of understanding to harmonize medical product regulation across the bloc.
Why it matters
The framework seeks to create a more predictable, quality-led ecosystem for clinical research and innovation across member states. By aligning operational requirements, participating nations aim to improve the long-term availability and safety of medical products.
The framework was introduced at the 18th annual BRICS Summit, consolidating diverse national approaches into a singular GxP white paper. This expansion follows India’s 2019 implementation of its New Drugs and Clinical Trials Rules.
The players
BRICS Regulatory Authorities
A collaborative body representing the national drug regulatory agencies of Brazil, Russia, India, China, and South Africa.
India
A major pharmaceutical manufacturing hub that hosted the 18th annual BRICS Summit and enacted the 2019 New Drugs and Clinical Trials Rules.
The details
Regulatory authorities from the member nations consolidated their technical approaches to create the shared GxP documentation. This move synchronizes quality systems and operational processes, designed to facilitate cross-border innovation. The framework supports existing efforts like India’s Biopharma SHAKTI initiative by providing a unified regulatory baseline for clinical and manufacturing activities.
Timeline
2019: India enacted the New Drugs and Clinical Trials Rules.
2026: The 18th annual BRICS Summit occurred in India.
Market Landscape
The new GxP framework extends the regulatory rigor previously seen in the 2019 New Drugs and Clinical Trials Rules to a broader multinational bloc. It marks a shift from isolated national oversight to a coordinated strategy for clinical research and quality-led innovation.
Operators in the biopharma space should track how these GxP standards are adopted in their specific jurisdictions to anticipate changes in compliance requirements. Aligning internal quality systems with these consolidated international norms may become necessary for businesses participating in cross-border clinical trials.
The takeaway
The GxP framework serves as a signal that the bloc is prioritizing harmonized quality systems to compete as a global hub for innovation. Companies should monitor their respective national agencies for local rule-making updates that adopt the provisions of the New Delhi Declaration.
Further reading
For more background on how regulatory updates shape regional business environments, visit the Economic Policy section.
Source note: This article includes information reported by FortuneIndia.
Live Poll
Do you believe international collaboration on clinical research standards will result in better medical innovation?
